Spinal activation of delta opioid receptors alleviates cancer-related bone pain

Neuroscience

Volumn 183, Issue , 2011, Pages 221-229

  Otis, V ^a   Sarret, P ^a,b   Gendron, L ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Allodynia; Bone cancer; Complete freund's adjuvant; Delta opioid receptor; MRMT 1 cells; Pain

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTORPHIN II; FREUND ADJUVANT; NALTRINDOLE; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BONE CANCER; BONE FRAGILITY; CANCER PAIN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; MALE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; RAT; TREATMENT RESPONSE;

ANALGESICS, OPIOID; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERALGESIA; INFLAMMATION; INJECTIONS, SPINAL; MALE; OLIGOPEPTIDES; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; TIME FACTORS;

EID: 79955581982     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.052     Document Type: Article

References (57)

1. Baamonde A., Lastra A., Juarez L., Garcia V., Hidalgo A., Menendez L. Effects of the local administration of selective mu-, delta- and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol 2005, 372:213-219.
2. Brainin-Mattos J., Smith N.D., Malkmus S., Rew Y., Goodman M., Taulane J., Yaksh T.L. Cancer-related bone pain is attenuated by a systemically available delta-opioid receptor agonist. Pain 2006, 122:174-181.
3. Cahill C.M., Morinville A., Hoffert C., O'Donnell D., Beaudet A. Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control. Pain 2003, 101:199-208.
4. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63.
5. Christo P.J., Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci 2008, 1138:278-298.
6. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
7. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
8. de Wit R., van Dam F., Litjens M.J., Abu-Saad H.H. Assessment of pain cognitions in cancer patients with chronic pain. J Pain Symptom Manage 2001, 22:911-924.
9. Debruyne D., Leroy A., Vakaet L., Mareel M., Bracke M. Direct effects of delta opioid receptor agonists on invasion-associated activities of HCT-8/E11 colon cancer cells. Anticancer Res 2010, 30:9-17. O, DEW.
10. Dixon W.J. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980, 20:441-462.
11. Dixon W.J. Staircase bioassay: the up-and-down method. Neurosci Biobehav Rev 1991, 15:47-50.
12. Donovan-Rodriguez T., Dickenson A.H., Urch C.E. Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neurosci Lett 2004, 360:29-32.
13. Dore-Savard L., Otis V., Belleville K., Lemire M., Archambault M., Tremblay L., Beaudoin J.F., Beaudet N., Lecomte R., Lepage M., Gendron L., Sarret P. Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PLoS One 2010, 5:e13774.
14. Fraser G.L., Pradhan A.A., Clarke P.B., Wahlestedt C. Supraspinal antinociceptive response to [d-Pen(2,5)]-enkephalin (DPDPE) is pharmacologically distinct from that to other delta-agonists in the rat. J Pharmacol Exp Ther 2000, 295:1135-1141.
15. Gaveriaux-Ruff C., Karchewski L.A., Hever X., Matifas A., Kieffer B.L. Inflammatory pain is enhanced in delta opioid receptor-knockout mice. Eur J Neurosci 2008, 27:2558-2567.
16. Gendron L., Esdaile M.J., Mennicken F., Pan H., O'Donnell D., Vincent J.P., Devi L.A., Cahill C.M., Stroh T., Beaudet A. Morphine priming in rats with chronic inflammation reveals a dichotomy between antihyperalgesic and antinociceptive properties of deltorphin. Neuroscience 2007, 144:263-274.
17. Gendron L., Lucido A.L., Mennicken F., O'Donnell D., Vincent J.P., Stroh T., Beaudet A. Morphine and pain-related stimuli enhance cell surface availability of somatic delta-opioid receptors in rat dorsal root ganglia. J Neurosci 2006, 26:953-962.
18. Gendron L., Pintar J.E., Chavkin C. Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. Neuroscience 2007, 150:807-817.
19. Halvorson K.G., Sevcik M.A., Ghilardi J.R., Rosol T.J., Mantyh P.W. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 2006, 22:587-600.
20. Holdridge S.V., Cahill C.M. Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Eur J Pain 2007, 11:685-693.
21. Honore P., Mantyh P.W. Bone cancer pain: from mechanism to model to therapy. Pain Med 2000, 1:303-309.
22. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98:585-598.
23. Hurley R.W., Hammond D.L. The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. J Neurosci 2000, 20:1249-1259.
24. Jaglowski J.R., Zagon I.S., Stack B.C., Verderame M.F., Leure-duPree A.E., Manning J.D., McLaughlin P.J. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2005, 56:97-104.
25. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
26. King T., Vardanyan A., Majuta L., Melemedjian O., Nagle R., Cress A.E., Vanderah T.W., Lai J., Porreca F. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 2007, 132:154-168.
27. Kirou-Mauro A.M., Hird A., Wong J., Sinclair E., Barnes E.A., Tsao M., Danjoux C., Chow E. Has pain management in cancer patients with bone metastases improved?. A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 2009, 37:77-84.
28. Krames E.S., Wilkie D.J., Gershow J. Intrathecal d-Ala2-d-Leu5-enkephalin (DADL) restores analgesia in a patient analgetically tolerant to intrathecal morphine sulfate. Pain 1986, 24:205-209.
29. Kuniyasu H., Luo Y., Fujii K., Sasahira T., Moriwaka Y., Tatsumoto N., Sasaki T., Yamashita Y., Ohmori H. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut 2010, 59:348-356.
30. Luger N.M., Sabino M.A., Schwei M.J., Mach D.B., Pomonis J.D., Keyser C.P., Rathbun M., Clohisy D.R., Honore P., Yaksh T.L., Mantyh P.W. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 2002, 99:397-406.
31. Mantyh P.W., Clohisy D.R., Koltzenburg M., Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002, 2:201-209.
32. Martin-Kleiner I., Gabrilovac J., Kusec R., Boranic M. Methionine enkephalin suppresses metabolic activity of a leukemic cell line (NALM-1) and enhances CD10 expression. Int Immunopharmacol 2003, 3:707-711.
33. Martin M., Matifas A., Maldonado R., Kieffer B.L. Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. Eur J Neurosci 2003, 17:701-708.
34. Medhurst S.J., Walker K., Bowes M., Kidd B.L., Glatt M., Muller M., Hattenberger M., Vaxelaire J., O'Reilly T., Wotherspoon G., Winter J., Green J., Urban L. A rat model of bone cancer pain. Pain 2002, 96:129-140.
35. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997, 69:1-18.
36. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol 2010, 11:484-489.
37. Mercadante S., Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998, 24:425-432.
38. Mercadante S., Ferrera P., Villari P., Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003, 26:769-775.
39. Meuser T., Pietruck C., Radbruch L., Stute P., Lehmann K.A., Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93:247-257.
40. Mika J., Przewlocki R., Przewlocka B. The role of delta-opioid receptor subtypes in neuropathic pain. Eur J Pharmacol 2001, 415:31-37.
41. Morinville A., Cahill C.M., Aibak H., Rymar V.V., Pradhan A., Hoffert C., Mennicken F., Stroh T., Sadikot A.F., O'Donnell D., Clarke P.B., Collier B., Henry J.L., Vincent J.P., Beaudet A. Morphine-induced changes in delta opioid receptor trafficking are linked to somatosensory processing in the rat spinal cord. J Neurosci 2004, 24:5549-5559.
42. Morinville A., Cahill C.M., Kieffer B., Collier B., Beaudet A. Mu-opioid receptor knockout prevents changes in delta-opioid receptor trafficking induced by chronic inflammatory pain. Pain 2004, 109:266-273.
43. Moulin D.E., Max M.B., Kaiko R.F., Inturrisi C.E., Maggard J., Yaksh T.L., Foley K.M. The analgesic efficacy of intrathecal d-Ala2-d-Leu5-enkephalin in cancer patients with chronic pain. Pain 1985, 23:213-221.
44. Nadal X., Banos J.E., Kieffer B.L., Maldonado R. Neuropathic pain is enhanced in delta-opioid receptor knockout mice. Eur J Neurosci 2006, 23:830-834.
45. Onofrio B.M., Yaksh T.L. Intrathecal delta-receptor ligand produces analgesia in man. Lancet 1983, 1:1386-1387.
46. Ossipov M.H., Lai J., King T., Vanderah T.W., Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 2005, 80:319-324.
47. Petrillo P., Angelici O., Bingham S., Ficalora G., Garnier M., Zaratin P.F., Petrone G., Pozzi O., Sbacchi M., Stean T.O., Upton N., Dondio G.M., Scheideler M.A. Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]iso quinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses. J Pharmacol Exp Ther 2003, 307:1079-1089.
48. Porreca F., Heyman J.S., Mosberg H.I., Omnaas J.R., Vaught J.L. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [d-Pen2, d-Pen5]enkephalin in the mouse. J Pharmacol Exp Ther 1987, 241:393-400.
49. Portenoy R.K., Lesage P. Management of cancer pain. Lancet 1999, 353:1695-1700.
50. Ruiz-Garcia V., Lopez-Briz E. Morphine remains gold standard in breakthrough cancer pain. BMJ 2008, 337:a3104.
51. Schulman K.L., Kohles J. Economic burden of metastatic bone disease in the US. Cancer 2007, 109:2334-2342.
52. Silverman S.M. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009, 12:679-684.
53. Stewart P.E., Hammond D.L. Activation of spinal delta-1 or delta-2 opioid receptors reduces carrageenan-induced hyperalgesia in the rat. J Pharmacol Exp Ther 1994, 268:701-708.
54. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 2004, 18:267-274.
55. Wacnik P.W., Kehl L.J., Trempe T.M., Ramnaraine M.L., Beitz A.J., Wilcox G.L. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain 2003, 101:175-186.
56. Yamamoto J., Kawamata T., Niiyama Y., Omote K., Namiki A. Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 2008, 151:843-853.
57. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009, 3:1-6.